Startseite A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels

  • Eun-Kee Park , Donald Wilson und Deborah H. Yates EMAIL logo
Veröffentlicht/Copyright: 15. Juli 2012
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM) Band 50 Heft 12

Abstract

Background: Malignant mesothelioma (MM) is an aggressive pleural tumor which is difficult to diagnose in its early stages. Thus, biomarkers for MM including soluble mesothelin-related protein (SMRP) are currently an area of intense research interest. However, SMRP is affected by several factors other than malignancy which need to be taken into account in the individual patient. This study aimed to evaluate factors required to adjust SMRP levels for such variables and produce a useful prediction equation for clinical application.

Methods: Serum SRMP levels were measured in 535 subjects formerly exposed to asbestos and silica, including many with asbestos-related disorders (ARDs). Linear regression analyses were used to quantify the strength and “direction” of the relationship between SMRP and several independent variables, and 2×2 tables were used to determine the diagnostic accuracy of SMRP levels, taking into account clinical variables.

Results: SMRP levels were affected by age and glomerular filtration rate (GFR), which were strong confounders in this study. Body mass index (BMI) was also an initial confounder but lost significance after other factors were taken into account. SMRP was also affected by smoking. Poor sensitivity (15.1%) for SMRP values among subjects with non-malignant asbestos-related disorders was found when compared to currently healthy subjects with a history of asbestos exposure.

Conclusions: The present study proposes an equation based on age and GFR to improve diagnostic accuracy of SMRP. The poor sensitivity of SMRP found in this study suggests that further work is needed to find new candidate biomarkers for diagnosing early stage MM.

Keywords: asbestos; biomarker; screening; sensitivity; soluble mesothelin-related protein
Corresponding author: Deborah H. Yates, MBBChir MSc AFOM Dip Occ Med MD FRACP FRCP, Department of Thoracic Medicine, St Vincent’s Hospital, Darlinghurst, Sydney, NSW 2010, Australia Phone: +61 2 83822330, Fax: +61 2 83822505

This study was supported by the Kosin Medical School and the Lesley Pockley Clinical Research Trust.

Conflict of interest statement

Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article. Research support played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

References

1. Martino D, Pass HI. Integration of multimodality approaches in the management of malignant pleural mesothelioma. Clin Lung Cancer 2004;5:290–8.10.3816/CLC.2004.n.008Suche in Google Scholar PubMed

2. Hyland RA, Ware S, Johnson AR, Yates DH. Incidence trends and gender differences in malignant mesothelioma in New South Wales, Australia. Scand J Work Environ Health 2007;33: 286–92.10.5271/sjweh.1145Suche in Google Scholar PubMed

3. Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 2008;3: 851–7.10.1097/JTO.0b013e318180477bhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000258447300007&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Suche in Google Scholar PubMed

4. Cristaudo A, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, et al. Combined serum mesothelin and plasma ostepontin measurements in malignant pleural mesothelioma. J Thorac Oncol 2011;6:1587–93.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000294008000021&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1097/JTO.0b013e31821e1c08Suche in Google Scholar PubMed

5. Hollevoet K, Nackaerts K, Thimpont J, Germonpré P, Bosquée L, De Vuyst P, et al. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med 2010;181:620–5.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000280446500016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1164/rccm.200907-1020OCSuche in Google Scholar PubMed

6. Park EK, Sandrini A, Yates DH, Creaney J, Robinson BW, Thomas PS, et al. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am J Respir Crit Care Med 2008;178:832–7.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000259932600010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1164/rccm.200802-258OCSuche in Google Scholar PubMed

7. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005;353:1564–73.10.1056/NEJMoa051185Suche in Google Scholar PubMed

8. Rai AJ, Flores RM, Mathew A, Gonzalez-Espinoza R, Bott N, Ladanyi M, et al. Soluble mesothelin-related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels. Clin Chem Lab Med 2010;48:271–8http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000274286000019&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1515/CCLM.2010.066Suche in Google Scholar PubMed

9. Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol 2008;3:1317–24.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000261113500016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1097/JTO.0b013e318187491cSuche in Google Scholar PubMed

10. Beyer HL, Geschwindt RD, Glover CL, Tran L, Hellstrom I, Hellstrom KE, et al. MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem 2007;53:666–72.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000245640400017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1373/clinchem.2006.079327Suche in Google Scholar PubMed

11. Boudville N, Paul R, Robinson BW, Creaney J. Mesothelin and kidney function-analysis of relationship and implications for mesothelioma screening. Lung Cancer 2011;73:320–4.10.1016/j.lungcan.2011.01.011http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000294101000012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Suche in Google Scholar PubMed

12. Hollevoet K, Nackaerts K, Thas O, Thimpont J, Germonpré P, De Vuyst P, et al. The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor. Chest 2012;141:477–84.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000299917900027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1378/chest.11-0129Suche in Google Scholar PubMed

13. Park EK, Thomas PS, Creaney J, Johnson AR, Robinson BW, Yates DH. Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population. Clin Chem Lab Med 2010;48:869–74.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000279342700021&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Suche in Google Scholar

14. Weber DG, Johnen G, Taeger D, Weber A, Gross IM, Pesch B, et al. Assessment of confounding factors affecting the tumor markers SMRP, CA125, and CYFRA21-1 in serum. Biomark Insights 2010;5:1–8.10.4137/BMI.S3927Suche in Google Scholar PubMed PubMed Central

15. Hollevoet K, Bernard D, De Geeter F, Walgraeve N, van den Eeckhaut A, Vanholder R, et al. Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum. Clin Chem 2009;55:1431–3.10.1373/clinchem.2008.121913Suche in Google Scholar PubMed

16. American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med 2004;170:691–715.10.1164/rccm.200310-1436STSuche in Google Scholar PubMed

17. Amati M, Tomasetti M, Scartozzi M, Mariotti L, Alleva R, Pignotti E, et al. Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study. Cancer Epidemiol Biomarkers Prev 2008;17:163–70.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000252503900021&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1158/1055-9965.EPI-07-0607Suche in Google Scholar PubMed

18. Creaney J, Christansen H, Lake R, Musk AB, de Klerk N, Robinson BW. Soluble mesothelin related protein in mesothelioma. J Thorac Oncol 2006;1:172–4.10.1097/01243894-200602000-00013Suche in Google Scholar

19. Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 2007;132:1239–46.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000250254000024&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1378/chest.07-0013Suche in Google Scholar PubMed

20. Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, et al. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007;62:569–76.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000247620800004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1136/thx.2006.068114Suche in Google Scholar PubMed PubMed Central

21. Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007;13:5076–81.10.1158/1078-0432.CCR-07-0629http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000249287700020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Suche in Google Scholar PubMed

22. Di Serio F, Fontana A, Loizzi M, Capotorto G, Maggiolini P, Mera E, et al. Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results. Clin Chem Lab Med 2007;45: 634–8.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000247005900011&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Suche in Google Scholar

23. Grigoriu B, Chahine B, Zerimech F, Grégoire M, Balduyck M, Copin MC, et al. Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. Clin Biochem 2009;42:1046–50.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000267274300018&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1016/j.clinbiochem.2009.03.007Suche in Google Scholar PubMed

24. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007;13:2928–35.10.1158/1078-0432.CCR-06-2144http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000246572600016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Suche in Google Scholar PubMed

25. Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008;85:265–72.10.1016/j.athoracsur.2007.07.042http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000251837400038&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Suche in Google Scholar PubMed

26. Rodríguez Portal JA, Rodríguez Becerra E, Rodríguez Rodríguez D, Alfageme Michavila I, Quero Martínez A, Diego Roza C, et al. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev 2009;18:646–50.10.1158/1055-9965.EPI-08-0422http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000263547800037&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Suche in Google Scholar PubMed

27. Scherpereel A, Grigoriu B, Conti M, Gey T, Grégoire M, Copin MC, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;15:1155–60.10.1164/rccm.200511-1789OCSuche in Google Scholar PubMed

28. Van den Heuvel MM, Korse CM, Bonfrer JM, Bass P. Non-invasive diagnosis of pleural malignancies: the role of tumour markers. Lung Cancer 2008;59:350–4.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000255606900008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1016/j.lungcan.2007.08.030Suche in Google Scholar PubMed

29. Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012;30:1541–9.10.1200/JCO.2011.39.6671http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000303859400026&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Suche in Google Scholar PubMed PubMed Central

30. Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, et al. Soluble-mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 2010;28:3316–22.10.1200/JCO.2009.26.9944http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000279637600018&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Suche in Google Scholar PubMed

31. Chapman EA, Thomas PS, Stone E, Lewis C, Yates DH. A breath test for malignant mesothelioma using an electronic nose. Eur Respir J 2011 Dec 19 [Epub ahead of print]. DOI: 10.1183/09031936.00040911.10.1183/09031936.00040911http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000307291700025&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Suche in Google Scholar PubMed

32. Yamada S, Tabata C, Tabata R, Fukuoka K, Nakano T. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma. Clin Chem Lab Med 2011;49:1721–6.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000296591500019&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Suche in Google Scholar PubMed

Received: 2012-05-16
Accepted: 2012-06-24
Published Online: 2012-07-15
Published in Print: 2012-12-01

©2012 by Walter de Gruyter Berlin Boston

Artikel in diesem Heft

  1. Masthead
  2. Masthead
  3. Editorials
  4. Phlebotomy, stat testing and laboratory organization: an intriguing relationship
  5. Human epididymis protein 4: the start of a post-ROMAn era?
  6. Hyperhomocysteinemia in health and disease: where we are now, and where do we go from here?
  7. Reviews
  8. The usefulness of cystatin C and related formulae in pediatrics
  9. The emerging role of biomarkers and bio-impedance in evaluating hydration status in patients with acute heart failure
  10. Biomarkers in primary open angle glaucoma
  11. Mini Review
  12. Identification of circulating microRNAs as biomarkers in cancers: what have we got?
  13. Opinion Paper
  14. HE4 in gynecological cancers: report of a European investigators and experts meeting
  15. Guidelines and Recommendations
  16. Position paper on laboratory testing for patients taking new oral anticoagulants. Consensus document of FCSA, SIMeL, SIBioC and CISMEL1)
  17. General Clinical Chemistry and Laboratory Medicine
  18. Reducing the number of clinical stat phlebotomy orders: feasible or not?
  19. Calculating acid-base and oxygenation status during COPD exacerbation using mathematically arterialised venous blood
  20. UrineCART, a machine learning method for establishment of review rules based on UF-1000i flow cytometry and dipstick or reflectance photometer
  21. Reference Values and Biological Variations
  22. Assessing seasonality in clinical research
  23. Cancer Diagnostics
  24. Identification of a novel in-frame deletion in BRCA2 and analysis of variants of BRCA1/2 in Italian patients affected with hereditary breast and ovarian cancer
  25. Human epididymis protein 4 (HE4) in benign and malignant diseases
  26. Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome
  27. A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels
  28. Cardiovascular Diseases
  29. Vitamin D deficiency parallels inflammation and immune activation, the Ludwigshafen Risk and Cardiovascular Health (LURIC) study
  30. Plasma homocysteine and the risk of venous thromboembolism: insights from the FIELD study
  31. Letters to the Editor
  32. A two-base-pairs deletion in the albumin gene causes a new case of analbuminemia
  33. Usefulness of an antiglycolytic granular mixture of sodium fluoride and citrate for stabilizing plasma homocysteine levels
  34. Further insights on the relationship between bilirubin and C-reactive protein
  35. Phosphoethanolamine normal range in pediatric urines for hypophosphatasia screening
  36. Risk of false positive hepatitis C virus RNA due to sample to sample carryover on an automated hematology analyzer
  37. Lack of commutability between a quality control material and plasma samples in a troponin I measurement system
  38. Biological variation in pregnancy-associated plasma protein-A in healthy men and non-pregnant healthy women
  39. Investigation of a slope discontinuity in a patients’ results distribution for D-dimer
  40. Acknowledgment
  41. Acknowledgment
https://doi.org/10.1515/cclm-2012-0314
Schlagwörter für diesen Artikel
asbestos; biomarker; screening; sensitivity; soluble mesothelin-related protein

Artikel in diesem Heft

  1. Masthead
  2. Masthead
  3. Editorials
  4. Phlebotomy, stat testing and laboratory organization: an intriguing relationship
  5. Human epididymis protein 4: the start of a post-ROMAn era?
  6. Hyperhomocysteinemia in health and disease: where we are now, and where do we go from here?
  7. Reviews
  8. The usefulness of cystatin C and related formulae in pediatrics
  9. The emerging role of biomarkers and bio-impedance in evaluating hydration status in patients with acute heart failure
  10. Biomarkers in primary open angle glaucoma
  11. Mini Review
  12. Identification of circulating microRNAs as biomarkers in cancers: what have we got?
  13. Opinion Paper
  14. HE4 in gynecological cancers: report of a European investigators and experts meeting
  15. Guidelines and Recommendations
  16. Position paper on laboratory testing for patients taking new oral anticoagulants. Consensus document of FCSA, SIMeL, SIBioC and CISMEL1)
  17. General Clinical Chemistry and Laboratory Medicine
  18. Reducing the number of clinical stat phlebotomy orders: feasible or not?
  19. Calculating acid-base and oxygenation status during COPD exacerbation using mathematically arterialised venous blood
  20. UrineCART, a machine learning method for establishment of review rules based on UF-1000i flow cytometry and dipstick or reflectance photometer
  21. Reference Values and Biological Variations
  22. Assessing seasonality in clinical research
  23. Cancer Diagnostics
  24. Identification of a novel in-frame deletion in BRCA2 and analysis of variants of BRCA1/2 in Italian patients affected with hereditary breast and ovarian cancer
  25. Human epididymis protein 4 (HE4) in benign and malignant diseases
  26. Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome
  27. A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels
  28. Cardiovascular Diseases
  29. Vitamin D deficiency parallels inflammation and immune activation, the Ludwigshafen Risk and Cardiovascular Health (LURIC) study
  30. Plasma homocysteine and the risk of venous thromboembolism: insights from the FIELD study
  31. Letters to the Editor
  32. A two-base-pairs deletion in the albumin gene causes a new case of analbuminemia
  33. Usefulness of an antiglycolytic granular mixture of sodium fluoride and citrate for stabilizing plasma homocysteine levels
  34. Further insights on the relationship between bilirubin and C-reactive protein
  35. Phosphoethanolamine normal range in pediatric urines for hypophosphatasia screening
  36. Risk of false positive hepatitis C virus RNA due to sample to sample carryover on an automated hematology analyzer
  37. Lack of commutability between a quality control material and plasma samples in a troponin I measurement system
  38. Biological variation in pregnancy-associated plasma protein-A in healthy men and non-pregnant healthy women
  39. Investigation of a slope discontinuity in a patients’ results distribution for D-dimer
  40. Acknowledgment
  41. Acknowledgment
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 17.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2012-0314/html
Button zum nach oben scrollen